Henderson Morley takes aim at those pesky microscopic parasites we know as viruses. The company researches and develops vaccines and treatments for viral infections by preventing them from replicating once they invade their host cells. One of its lead product candidates is a vaccine for genital herpes that could be used as a preventative or a therapeutic measure. Other candidates target human cytomegalovirus and human papillomavirus. Instead of taking its candidates through all phases of development, Henderson Morley instead looks to out-license its candidates. Chairman Andrew Knight owns 34% of the company.

Allergan, Inc. was founded in 1948 and is headquartered in Irvine, California. Allergan, Inc., a multi-specialty healthcare company, discovers, develops, and commercializes specialty pharmaceutical, medical device, and over-the-counter products for the ophthalmic, neurological, medical aesthetics, medical dermatological, breast aesthetics, obesity intervention, urological, and other specialty markets worldwide. It operates in two segments, Specialty Pharmaceuticals and Medical Devices. The Specialty Pharmaceuticals segment offers a range of pharmaceutical products, including ophthalmic products for chronic dry eye, glaucoma therapy, ocular inflammation, infection, and allergy; Botox for the therapeutic and aesthetic indications; skin care products for acne, psoriasis, and other skin care products; eyelash growth products; and urologics products. The Medical Devices segment offers a range of medical devices, such as breast implants for augmentation, revision, and reconstructive surgery; obesity intervention products, including the Lap-Band System and the BIB BioEnterics Intragastric Balloon; and facial aesthetics products.Allergan company also offers Contigen for the treatment of urinary incontinence due to intrinsic sphincter deficiency. It sells its products to drug wholesalers, independent and chain drug stores, pharmacies, commercial optical chains, opticians, mass merchandisers, food stores, hospitals, group purchasing organizations, integrated direct hospital networks, and ambulatory surgery centers, as well as to medical practitioners, including ophthalmologists, neurologists, dermatologists, plastic and reconstructive surgeons, aesthetic specialty physicians, bariatric surgeons, pediatricians, urologists, and general practitioners. Allergan, Inc. has strategic research collaboration agreements with ExonHit Therapeutics S.A.; Spectrum Pharmaceuticals, Inc.; and Pieris AG.

Genome Explorations Inc. was founded by Dr. Divyen H. Patel to provide academic and industrial institutes with a 'Complete Solution' for Genotyping, Gene expression and miRNA profiling. Dr. Patel initiated and ran the Affymetrix GeneChip processing core at St. Jude Children's Research Hospital. The finding's from one of the many studies conducted through his core was described in a seminal study on the cover of Cancer Cell (Cancer Cell Vol. 1 133-143 March 2002). The study showed for the first time that microarray technology could be used to enhance diagnosis of pediatric leukemia and could also be used to evaluate prognostic outcome. The extensive experience gained through working with scores of investigators on many varying projects has made Genome Explorations Inc. the number one choice for Investigators worldwide.

Acorda Therapeutics, Inc. (Acorda) is a commercial-stage biopharmaceutical company engaged in the identification, development and commercialization of therapies that improve neurological function in people with multiple sclerosis (MS), spinal cord injury (SCI), and other disorders of the central nervous system (CNS). The Company’s marketed product, Zanaflex Capsules, is approved by the United States Food and Drug Administration (FDA) for the management of spasticity. The Company’s product candidate Fampridine-SR, has completed two positive Phase III clinical trials for the improvement of walking ability in patients with MS. The research and development programs for the Company include Remyelination Programs and Chondroitinase Program.

Æterna Zentaris Inc. company was founded in 1991 and is headquartered in Quebec, Canada. Æterna Zentaris Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for endocrine therapy and oncology. Its lead product candidates in endocrinology are cetrorelix, a luteinizing hormone-releasing hormone (LHRH) antagonist that has completed Phase III trial for benign prostatic hyperplasia (BPH); and AEZS-130, an oral ghrelin antagonist in a Phase III trial as a diagnostic test for Growth Hormone Deficiency. Æterna Zentaris company's lead products in cancer are perifosine, a PI3K/Akt pathway inhibitor in Phase III for multiple myeloma, and AEZS-108, a Phase II clinical trial product for the treatment of advanced ovarian and endometrial cancers, as well as AEZS-112 that is in a Phase I trial in advanced solid tumors and lymphoma. Its pipeline also include compounds in pre clinical development, such as AEZS-115, an LHRH antagonist for endometriosis and urology; AEZS-120, an anti-cancer vaccine; AEZS-126 Erk and PI3K inhibitors for oncology; and AEZS-127 ErPC for oncology. Æterna Zentaris has partnership agreements with Shionogi and Co.; sanofi-aventis; Nippon Kayaku Co. Ltd.; Spectrum Pharmaceuticals, Inc.; Handok Pharmaceuticals Co., Ltd.; and Keryx Biopharmaceuticals, Inc.

Eisai develops, manufactures, and distributes prescription pharmaceuticals, primarily in North America and Japan. Prescription drug sales account for a majority of the company's revenues and are led by Aricept, which treats Alzheimer's disease. Other drugs include Myonal, a muscle relaxant, and AcipHex, an acid reflux and ulcer treatment (sold as Pariet in Japan and Europe). Development programs target neurology, oncology, vascular, and immunological ailments. In Japan the company distributes generic and non-prescription drugs and consumer health products. Eisai also makes food additives and chemicals, in addition to drug manufacturing equipment and systems.

Since its founding in 2004, Anthera Pharmaceuticals' operations have consisted primarily of research and development activities. A biopharmaceutical company, Anthera Pharmaceuticals develops drug treatments for respiratory, cardiovascular, and immunological diseases. Its current candidates, which are in various phases of clinical development, include therapies for acute coronary syndrome (inflammation of heart muscle), lupus, and sickle cell disease. The company also has treatments for asthma and dermatitis in earlier stages of development. The company filed an initial public offering (IPO) in mid-2009.

SIGA Technologies was founded in 1995 and is headquartered in New York, New York. SIGA Technologies, Inc., a biotechnology company, engages in the discovery, development, and commercialization of anti-infectives and antibiotics for the prevention and treatment of serious infectious diseases. SIGA company focus on products for use in defense against biological warfare agents, such as smallpox, arenaviruses (hemorrhagic fevers), and other category A viral agents. Its lead product, ST-246, is an orally administered anti-viral drug that targets orthopox viruses. SIGA's product candidates also include ST-294 and ST-193, which demonstrates antiviral activity in cell culture assays against arenavirus pathogens; and ST-669, a broad spectrum antiviral candidate, for various viruses in the Poxviridae, Filoviridae, Bunyaviridae, Arenaviridae, Flaviviridae, Togaviridae, Retroviridae, and Picornaviridae families. In addition, it also has four drug series in the pre-clinical development stage, including ST-610 and ST-148 for dengue virus of the genus Flavivirus. SIGA company has license agreements, collaborative research arrangements, and contracts with National Institutes of Health and the United States Air Force.

Sandoz International GmbH engages in the development, production, marketing, and distribution of generic medicines, pharmaceutical and biotechnological active substances, and anti-infectives in Germany and internationally. It offers products for various therapeutic areas, including cardiovascular system, central nervous system, gastrointestinal system, muscle and skeletal system, hormone therapy, and respiratory system. The company’s product portfolio ranges from various application forms, such as oral solids through technologies, including inhalers or injectables to transdermal patches, implants, and biopharmaceutical follow-ons. It sells its products to wholesalers, pharmacies, hospitals, and other healthcare outlets. Sandoz International GmbH was founded in 1886 and is headquartered in Holzkirchen, Germany. The company has research and development, and production sites in Boucherville, Canada; Buenos Aires, Argentina; Cambe and Taboao da Serra, Brazil; Holzkirchen/Rudolstadt and Barleben, Germany; Kolshet, Kalwe, and Mahad, India; Kundl and Schaftenau, Austria; Menges and Ljubljana, Slovenia; Wilson, North Carolina; Broomfield, Colorado; Gebze and Syntex, Turkey; and Strykow, Poland. Sandoz International GmbH operates as a subsidiary of Novartis AG.

Kyorin, founded in 1923, already has affiliates and subsidiaries in Germany and the US. KYORIN Co., Ltd. is a Japan-based holding company engaged in the manufacture and sale of pharmaceuticals. The Company operates in two business segments. The Pharmaceuticals segment is engaged in the manufacture, purchase and sale of pharmaceutical products, the evaluation of technologies, the inspection, analysis and negotiation of license affiliations, the manufacture of clinical testing products, as well as the research of new drugs and candidate compounds. The Others segment is involved in the development and sale of cosmetics, as well as raw materials of medicines and cosmetics, the promotion of sales, the planning and production of advertisements, the sale of packaging materials, in addition to the provision of advisory services and the operational management of funds.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.